Laird Norton Wetherby Wealth Management LLC Makes New $472,000 Investment in Inhibrx, Inc. (NASDAQ:INBX)

Laird Norton Wetherby Wealth Management LLC acquired a new stake in shares of Inhibrx, Inc. (NASDAQ:INBX - Free Report) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 30,656 shares of the company's stock, valued at approximately $472,000. Laird Norton Wetherby Wealth Management LLC owned about 0.21% of Inhibrx as of its most recent SEC filing.

Several other large investors have also recently modified their holdings of INBX. HighTower Advisors LLC bought a new position in shares of Inhibrx in the fourth quarter worth $12,039,000. Walleye Capital LLC purchased a new position in Inhibrx during the fourth quarter worth about $8,932,000. Slotnik Capital LLC bought a new position in Inhibrx in the 4th quarter worth about $5,975,000. Geode Capital Management LLC bought a new position in Inhibrx in the 4th quarter worth about $3,930,000. Finally, Caption Management LLC purchased a new stake in shares of Inhibrx in the 4th quarter valued at about $3,078,000. Hedge funds and other institutional investors own 82.46% of the company's stock.

Inhibrx Price Performance

INBX stock traded up $0.30 during midday trading on Wednesday, reaching $13.37. The company had a trading volume of 16,448 shares, compared to its average volume of 165,283. The firm has a 50-day moving average price of $12.57 and a 200-day moving average price of $13.61. The company has a market capitalization of $193.54 million and a P/E ratio of 0.11. Inhibrx, Inc. has a 1 year low of $10.80 and a 1 year high of $34.63.

Inhibrx (NASDAQ:INBX - Get Free Report) last announced its earnings results on Wednesday, May 14th. The company reported ($2.80) earnings per share (EPS) for the quarter, missing the consensus estimate of ($2.55) by ($0.25). On average, equities analysts predict that Inhibrx, Inc. will post 104.88 EPS for the current year.

Analyst Upgrades and Downgrades

Separately, JMP Securities restated a "market perform" rating on shares of Inhibrx in a research report on Thursday, May 15th.

Inhibrx Profile

Inhibrx, Inc, a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidate includes INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency.